It appears there’s a China biotech gold rush as U.S. investors and pharma giants look to the world’s second largest economy in a new quest for new drugs and new remedies. Everyone is talking about China right now. Almost 30 percent of Big Pharma deals worth at least $50 million upfront came from China last year. That’s up from 20 percent the year before and zero in 2019. In the span of just two days in December, Merck announced two licensing deals with Chinese companies, and that really got people’s attention. So what’s going on?
If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.
2 Responses
Everyone is talking about china right now. / Um… No we’re not. Sure are a lot of people talking about alternative health models and finding workable solutions to eliminate the influence of the medical industrial complex and corporate modeling though. But, believe what you want to believe, it’s a free country. (unlike china.) ‘A new quest for new drugs and new remedies.’ Can we have codeine back in cough syrups again and a general tone down of prohibition? That’s what the people want. A biotech gold rush? Projecting much? Because that’s not what local people are saying about the deplorable state of health and health care, not even close. Made to break chinese products now even more involved with health care? Are humans and our personal health profiles the new planned obsolescent item?
Stop buying $hit from china!!!! It’s only cheap because of slave labor. We might as well just hand our entire country over to them now and just get it over with. At this point it’s almost inevitable. Hopefully Trump shuts this $hit down immediately.